Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema Clear all
Not listed Phase 4 Interventional

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

NCT03747575
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 4:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

NCT00465699
View directory record Official record
Conditions
Eczema
Interventions
Topical B12 0.07%
Drug
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2007 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

NCT01602341
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID, AN2728 Topical Ointment, 0.5% BID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Fremont, California • Miami, Florida • Lousiville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

NCT04598269
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Treatment Resistant Dermatitis TaroIIR

NCT03050294
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Phone calls, Desoximetasone 0.25% spray
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 22, 2026, 4:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational

A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists

NCT02916888
View directory record Official record
Conditions
Eczema, Dermatitis, Dermatitis, Atopic, Genetic Disease, Inborn, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, Skin Diseases, Skin Diseases, Eczematous, Skin Diseases, Genetic
Interventions
Care provided by general pediatrician, Care provided by pediatric dermatologist
Other
Lead sponsor
Yale University
Other
Eligibility
Up to 7 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT06585202
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-2138
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Encino, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

NCT03824405
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BTX 1204, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
12 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Encino, California • Fremont, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

NCT01905631
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Aurstat Anti-Itch Hydrogel (Aurstat)
Drug
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03817190
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Placebo
Drug
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 22, 2026, 4:29 AM EDT
Not listed No phase listed Observational

Hand Sanitizer Effects on the Skin Barrier

NCT04525521
View directory record Official record
Conditions
Dermatitis Hand, Skin Abnormalities, Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Hand sanitizer and hand washing
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population

NCT01016106
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis Vulgaris
Interventions
Buccal Swab
Genetic
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Tape Transcriptome Methods in Children

NCT04180644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin tape strips
Other
Lead sponsor
National Jewish Health
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational

Clinical and Immunological Evaluation of Children With Allergies

NCT00102570
View directory record Official record
Conditions
Hypersensitivity, Immediate
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Beverly Hills, California • Encino, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

NCT04936113
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB-401
Biological
Lead sponsor
Forte Biosciences, Inc.
Industry
Eligibility
2 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
8
States / cities
Fremont, California • Lake City, Florida • Newnan, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

NCT05923099
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 4:29 AM EDT